13:39 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Adynxx planning Phase III for pain candidate despite Phase II miss

Adynxx Inc. (San Francisco, Calif.) said that although brivoligide (AYX1) missed the primary endpoint in the Phase II ADYX-004 trial to treat postsurgical pain, the company still sees a path to Phase III based on...
12:31 , Apr 12, 2018 |  BC Extra  |  Clinical News

Adynxx planning Phase III for pain candidate despite Phase II miss

Adynxx Inc. (San Francisco, Calif.) said that although brivoligide (AYX1) missed the primary endpoint in the Phase II ADYX-004 trial to treat postsurgical pain, the company still sees a path to Phase III based on...
19:53 , Mar 14, 2017 |  BC Week In Review  |  Clinical News

AYX1: Ph II ADYX-004 started

Adynxx began the double-blind, placebo-controlled, U.S. Phase II ADYX-004 trial to evaluate single intrathecal injections of 660 mg AYX1 given prior to intrathecal administration of spinal anesthetic for unilateral total knee arthroplasty in about 200...
23:59 , Jan 10, 2017 |  BC Extra  |  Financial News

Adynxx raises $16M in series B

Pain company Adynxx Inc. (San Francisco, Calif.) raised $16 million in a series B round led by new investor TPG Biotech. Existing investor Domain Associates also participated. Adynxx said it plans to start a Phase...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

AYX1: Phase IIb data

The double-blind, U.S. Phase IIb ADYX-003 trial in 120 patients who underwent knee replacement surgery showed that a single preoperative intrathecal injection of AYX1 plus standard of care (SOC) met the primary endpoint of reducing...
00:07 , Aug 12, 2015 |  BC Extra  |  Clinical News

Adynxx meets in pain relief Phase II

Adynxx Inc. (San Fransisco, Calif.) said AYX1 significantly reduced pain in a placebo-controlled Phase II trial to reduce acute and chronic pain. AYX1, a small synthetic dsDNA inhibitor of early growth response 1 ( EGR1...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

AYX1: Completed Phase II enrollment

Adynxx completed enrollment of 120 patients in the double-blind, placebo-controlled, U.S. Phase II ADYX003 trial evaluating single intrathecal injections of 660 and 1,100 mg AYX1 given prior to unilateral total knee replacement. Adynxx Inc. ,...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

AYX1: Phase II started

Adynxx began the double-blind, placebo-controlled, U.S. Phase II ADYX-003 trial to evaluate single intrathecal injections of 660 and 1,100 mg AYX1 given prior to unilateral total knee replacement in about 120 patients. AYX1 has Fast...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

AYX1: Completed Phase II enrollment

Adynxx completed enrollment of 102 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating single intrathecal injections of 110 and 330 mg AYX1 prior to unilateral total knee arthroplasty. AYX1 has Fast Track designation...
07:00 , Aug 5, 2013 |  BioCentury  |  Strategy

Antibiotic aggregator

Cubist Pharmaceuticals Inc. is buying a pair of antibiotics companies to gain two compounds as revenue drivers to fill the gap between Cubicin daptomycin and the company's Phase III pipeline. Cubist's task now is to...